Proton pump inhibitor use does not elevate dementia risk
Use of proton pump inhibitors (PPIs), even at higher cumulative levels, does not increase the risk for dementia, a recent study has shown.
The study included 3,484 elderly adults without baseline dementia (median age 74 years; 59 percent female) who were screened for dementia every 2 years. The prevalence of baseline PPI use was 30.5 percent (n=1,061).
Over a mean follow-up of 7.5±5.0 years, 827 cases of dementia were reported, resulting in an occurrence rate of 23.7 percent. Possible or probable Alzheimer’s disease was identified in 670 of these. There was no significant relationship between PPI use and the risk of dementia (p=0.66).
Cumulative use of PPI was also unrelated to dementia risk. For instance, those with 365 total standardized daily doses (TSDD; hazard ratio [HR], 0.87; 95 percent CI, 0.65–1.8) had a statistically comparable risk of dementia vs those with no PPI use.
TSDD of 1,095 (HR, 0.99; 0.75–1.30) and 1,825 (HR, 1.13; 0.82–1.56) likewise did not lead to significant changes in dementia risk. This suggested that 1, 3 and 5 years of cumulative PPI use did not increase the risk of dementia.
Levels of exposure, amount of PPI intake and duration of use were all also not significantly connected to the risk of dementia.
“Although there are other safety concerns with long-term PPI use, results from our study do not support that patients and clinicians should avoid these medications because of concern about dementia risk,” said researchers.